Compare Novo Nordisk A/S (NVO) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Direxion Daily Semiconductor Bull 3X Shares trades at $139.76 (market cap $24.42B). The key difference: Novo Nordisk A/S is far larger — about 6.8× Direxion Daily Semiconductor Bull 3X Shares's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Direxion Daily Semiconductor Bull 3X Shares for 15 Days on average.
| NVO | SOXL | |
|---|---|---|
Market Cap | $165.31B | $24.42B |
Volume | 11,432,838 | 100,232,380 |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $300.77 |
52-Week Low | $35.29 | $30.81 |
Typical Hold Time | 116 Days | 15 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $139.76, down 12.05% with a bearish technical signal. The fund faces volatility from its 3x leverage on semiconductor stocks, which have shown mixed performance amid strong AI demand but regulatory and market risks. Recent news highlights sector rebounds and institutional selling, while technical indicators show neutral oscillators and key support at $134.
Outlook is cautious due to leverage amplifying sector swings; opportunities exist if semiconductor fundamentals hold, but risks include tariff concerns and overcrowded trades. Investors should weigh high volatility against AI-driven growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
